Of the various heparin-based technologies, the CARMEDA ® BioActive Surface (CBAS ® Heparin Surface; Carmeda AB, Upplands Väsby, Sweden), has the most extensive publication history describing both basic biochemical mechanisms and clinical applications.

Carmeda BioActive Surface (also known as the CBAS Heparin Surface) is a registered, clinically proven technology for improvement of the performance of artificial materials used in blood-contacting medical devices.

Reproduction of information or data in any way or form, and specifically the use of texts, sections of text, imagery or videos, requires prior approval from Carmeda. Information on this server is provided "as is" without any warranty of any kind, either express or implied, including but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non Carmeda® BioActive Surface (also known as CBAS® Heparin Surface) Reference List. Upplands Väsby, Sweden: Carmeda AB; 2019. [Reference list] The following features and benefits of the CARMEDA ® BioActive Surface have been shown in published clinical studies and scientific papers:. Thromboresistant - By suppressing the coagulation mechanism the CARMEDA ® BioActive Surface reduces or eliminates thrombotic complications related to the exposure of blood to artificial materials (1, 2).

Carmeda cbas

The general principle of the CARMEDA ® BioActive Surface technology is to attach functionally active heparin to the blood contacting surfaces of medical devices. Heparin is covalently bound to the surface by end-point attachment. What is the abbreviation for Carmeda BioActive Surface? What does CBAS stand for?

Skip to main content

Nov 13, 2000 Use of the Carmeda BioActive Surface (CBAS) has been given approval by the Food and Drug Administration (FDA) in a pre-market approval expanded polytetrafluoroethylene using Carmeda® BioActive Surface technology (CBAS-ePTFE) as a means of improving vascular graft thromboresistance. point attachment mechanism (Carmeda BioActive Surface. [CBAS], Carmeda AB, Upplands Väsby; Sweden).1 Results of infrainguinal bypass with this A heparin-coated CPB circuit known as the Carmeda.

a centrifugal pump (Biomedicus [Medtronic Inc, Minneapolis, MN]) and a closed, fully heparinized circuit (Carmeda Bioactive Surface, CBAS [Medtronic Inc]).

Yii M(1), Gourlay T, Fleming J, Matata B, Taylor KM. Carmeda BioActive Surface (also known as the CBAS Heparin Surface) is a registered, clinically proven technology for improvement of the performance of artificial materials used in blood-contacting medical devices. The CBAS Heparin Surface stays on the surface and remains bioactive on the EXCOR pump at least up until 1 year. This is an important demonstration of coating durability and supports the mid-term and long-term clinical use as bridge-to-heart transplantation or to myocardial recovery.

Sweden . Phone: +46 (8) 505 512 00. info@carmeda.se Disposable and implantable medical devices, namely, vascular grafts, stent grafts, vascular stents; [ cardiopulmonary bypass circuits, centrifugal pump circuits, artificial hearts, ventricular assist devices, namely, external or implantable devices to replace or support the function of the heart; medical tubing for use in drainage, transfusion, and administering drugs, and filters and cannulae CARMEDA BioActive Surface (CBAS) Heparin Surface The CBAS Heparin Surface consists of heparin molecules that are covalently bonded to all stent surfaces by an “end-point attachment” method.
Sjukvard i stockholm

Carmeda AB hade intäkter om cirka 148 MSEK 2014/2015 och gjorde ett EBIT-resultat om produkt CBAS® används bland annat för att ytbelägga Gore Medi-. Carmeda hade 2014 intäkter på cirka 119 MSEK och gjorde ett EBIT-resultat om cirka 69 MSEK.

10, 11 For EXCOR, the CBAS Heparin Carmeda BioActive Surface (also known as the CBAS Heparin Surface) is a registered, clinically proven technology for improvement of the performance of artificial materials used in blood-contacting medical devices. The CBAS Heparin Surface has clinically shown a reduction of platelet deposition, a decrease in inflammatory responses, 9-11 and a reduction of thrombogenicity.
Olika slöjor inom islam

About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features Press Copyright Contact us Creators

Clinical applications of the CBAS Heparin Surface include short-term procedures such as cardiopulmonary bypass, 7 long-term procedures such as VADs, 8 and permanent implants such as vascular grafts and stent grafts. 9 The effectiveness in reducing surface-induced thrombosis and even inflammation has also been demonstrated in a number of in vitro studies. 10, 11 For EXCOR, the CBAS Heparin Carmeda BioActive Surface (also known as the CBAS Heparin Surface) is a registered, clinically proven technology for improvement of the performance of artificial materials used in blood-contacting medical devices. The CBAS Heparin Surface has clinically shown a reduction of platelet deposition, a decrease in inflammatory responses, 9-11 and a reduction of thrombogenicity.

Rfsu stockholm lediga jobb

Features & Benefits. The CARMEDA BioActive Surface is a clinically proven and lasting thromboresistant heparin coating that actively prevents platelet adhesion

CBAS abbreviation stands for Carmeda BioActive Surface.